As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, ...

Dr. Reddy’s Laboratories RDY and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & ...

Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming ...

Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

On behalf of the Board, I want to thank Marc for his invaluable contributions to AEON over the last several years and his dedication to exhaustively evaluating all opportunities for the Company to ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

Initiated analytical studies in Q4 2024to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Celltrion announced on the 10th that its biosimilar of the asthma and chronic spontaneous urticaria treatment Zolaire (XOLAIR, generic name omalizumab), named OMLYCLO (development code CT-P39 ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...